



SCIENTIFIC PROGRAM*

(*Subject to change)

Wednesday, 6 March, 2024

13:00-14:30	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)				
14:30-14:40	Break to Change Halls				
14:40-16:10	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
16:10-16:20	Break to Change Halls				
16:20-17:50	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)				
18:00-18:40	OPENING SESSION				
	<u>Moshe Phillips</u> - Opening Remarks <u>Melanie Davies</u> – A new era in the management of T2DM and obesity – Scanning what’s on the horizon				
18:40-19:00	OPENING EVENT				
19:00-20:00	NETWORKING RECEPTION (in the Exhibition Area)				

Thursday, 7 March, 2024

08:00-08:20	ONLINE FIRST RELEASE							
08:20-09:00	SCIENTIFIC SESSION - TBD							
09:00-10:00	PLENARY 1 - TOWARD THE FUTURE							
	<p>Moshe Phillip - From dream to reality - The Automated Insulin Delivery (AID) system</p> <p>Boris Kovatchev - Neural-Net artificial pancreas</p> <p>Camillo Ricordi - From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions</p>							
10:00-10:30	COFFEE BREAK, EXHIBITION & E-POSTERS							
10:30-12:00	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
12:00-13:00	LUNCH BREAK, EXHIBITION & E-POSTERS							
13:00-14:30	PARALLEL SESSION 1 AUTOMATED INSULIN DELIVERY IN TYPE 1 AND TYPE 2 DIABETES	PARALLEL SESSION 2 CGM DIABETES QUALITY MEASURES	PARALLEL SESSION 3 HYPOGLYCEMIA - ANY PROGRESS?	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	JDRF - PARALLEL SESSION 4 INTERNATIONAL CONSENSUS MONITORING GUIDANCE FOR PRESYMPTOMATIC (EARLY STAGE) TYPE 1 DIABETES	PARALLEL SESSION 5 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES	PARALLEL SESSION 6 COPING WITH OBESITY	ORAL 1
	<p>Anders Carlson – Use of AID in patients with type 2 diabetes</p> <p>Roman Hovorka - Fully closed-loop in type 1 and type 2 diabetes</p> <p>Bruce Bode - Management of glucose in the hospital with AID systems</p> <p>May Ng - Bringing technology to diabetes care - From evidence to policy</p>	<p>Irl Hirsch - What has the GMI taught us about A1C?</p> <p>Elisabeth Selvin - Should A1C still be a diagnostic criterion for diabetes in 2024?</p> <p>Gregg Simonson – CGM (GMI/TIR) as diabetes quality metrics</p> <p>Guido Freckmann - International standard for evaluation of CGM systems: Approach of the IFCC</p>	<p>Stephanie Amiel – CGM detection of hypoglycemia in diabetes management</p> <p>Simon Heller - Should the classification of hypoglycemia be updated?</p> <p>Pratik Choudhary - Implication of HypoMETRICS for reporting hypoglycemia in clinical trials</p> <p>Bastiaan de Galan - Impaired awareness of hypoglycemia</p>		<p>Moshe Phillip - The rationale for consensus monitoring guidance for presymptomatic type 1 diabetes</p> <p>Linda DiMeglio - Summary of the consensus monitoring guidance for presymptomatic type 1 diabetes</p> <p>Kirstine Bell - Implications for research and clinical care</p> <p>Emanuele Bosi - Population screening for type 1 diabetes is now a reality: An update from Italy</p>	<p>Teresa Rodriguez-Calvo</p> <p>- Role of viruses in pathogenesis of type 1 diabetes</p> <p>Stefan Bornstein - Islet Transplantation 2024</p> <p>Roberto Mallone - Benign autoimmunity & progression to type 1 diabetes</p> <p>Desmond Schatz – Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors</p>	<p>Emma Wilmot – Technology-supported behavior intervention in type 2 diabetes</p> <p>Max Nieuwdorp - A balanced view on microbiome in obesity</p> <p>Luca Busetto – Will new pharmacological treatment for obesity and early diabetes replace bariatric surgery?</p> <p>TBC</p>	

14:30-14:40	Break to Change Halls							
14:40-16:10	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)							
16:10-16:40	COFFEE BREAK, EXHIBITION & E-POSTERS							
16:40-18:10	PARALLEL INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)	PARALLEL SESSION 7 STANDARDIZATION OF PROS	ORALS 2	PARALLEL SESSION 8 ROLE OF TECHNOLOGY IN NORMAL HEALTHY AND IN GDM PREGNANCY	PARALLEL SESSION 9 THE EFFECT OF DIABETES ON BRAIN HEALTH	PARALLEL SESSION 10 HYBRID CLOSED-LOOP FOR TYPE 2 DIABETES: HURDLES AND BENEFITS	PARALLEL SESSION 11 ACCESSIBILITY AND DISPARITIES OF DIABETES THERAPY	ORALS 3
	<p><u>Oliver Schnell</u> - What PROs mean in routine clinical care</p> <p><u>Katharine Barnard-Kelly</u> - Consensus statement summary, navigating the maze of PROs</p> <p><u>Mary Murphy</u> - What inclusion of quality PRO assessment in clinical trials means to people with diabetes</p> <p><u>Alon Liberman</u> – Real world data from type 1 diabetes clinics</p>	<p><u>Celeste Durnwald</u> – Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes?</p> <p><u>Eleanor Scott</u> - CGM glucose trajectories associated with large and small for gestational age birthweight</p> <p><u>Helen Murphy</u> – Should everyone with type 1 diabetes be offered closed-loop during pregnancy?</p> <p><u>Yariv Yogev</u> - Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation?</p>	<p><u>Mark Strachan</u> - Update on diabetes-associated cognitive dysfunction</p> <p><u>Tali Cukierman-Yaffe</u> - Diagnosis & monitoring of brain health in people with diabetes</p> <p><u>Hertzel Gerstein</u> - Brain aging in people with diabetes - Possible intervention</p> <p><u>David Tanne</u> - Novel approaches and the role of technology in treating brain aging in people with diabetes</p>	<p><u>Yves Reznik</u> - Closed-loop as home care for type 2 diabetes: The Close study</p> <p><u>Charlotte Boughton</u> - Cumulated experience with CamAPS in type 2 diabetes</p> <p><u>Gregory Forlenza</u> - Real-world data on hybrid closed-loop (HCL) in type 2 diabetes</p> <p><u>Anne Peters</u> - Pod use for closed-loop in type 2 diabetes</p>	<p><u>Lori Laffel</u> - Interventions to reduce health disparities in diabetes device use</p> <p><u>V Mohan</u> – Innovating to use existing technologies under resourced settings</p> <p><u>Partha Kar</u> - Widening clinical use of diabetes tech in the UK</p> <p><u>Stuart Weinzimer</u> - Strategies to facilitate technology use in disadvantaged youth with diabetes</p> <p><u>Ananta Addala</u> - Solutions for equity: A call to action</p>			

Friday, 8 March, 2024

08:30-09:20	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)								
09:20-09:30	Break to change halls								
09:30-10:30	PARALLEL EUDF SESSION 12 AI DRIVEN CLINICAL DECISION SUPPORT SYSTEMS: POTENTIAL, CONCERNS AND WHAT TO EXPECT?	PARALLEL SESSION 13 DUAL AND TRIPLE AGONISTS IN DIABETES AND OBESITY	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	PARALLEL SESSION 14 SKIN PROBLEMS IN DIABETES	PARALLEL SESSION 15 WEEKLY INSULINS	PARALLEL SESSION 16 PRACTICAL USE OF CGM	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	ORALS 4	
	<p><u>Stefano Del Prato</u> – Welcome and introduction</p> <p><u>Lutz Heinemann</u> - AI for diabetes management and state-of-the art today</p> <p><u>Mia Barjamagic</u> - Potential & concerns linked to the use of AI from the PwD perspective</p> <p><u>Tadej Battelino</u> - Implementing AI: Roadmap and guidelines</p> <p>Q&A and Discussion</p>	<p><u>Viral Shah</u> – GLP-1RA and SGLT in type 1 diabetes</p> <p><u>Andrej Janež</u> – Incretins and taste</p> <p><u>Michael Camilleri</u> - Pharmacological intervention with dual and triple agonists in obesity: Clinical efficacy and effects on stomach emptying</p>		<p><u>Anna Korsgaard Berg</u> - Skin problems caused by diabetes devices</p> <p><u>Julia Mader</u> - Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/training and awareness of HCP and PwD</p> <p><u>Deirdre Fitzgerald Huges</u> - Shining a light on diabetic foot infections, development of novel photodynamic materials</p>	<p><u>Julio Rosenstock</u> – Update on weekly insulin Icodec: The way of the future</p> <p><u>Juan Frias</u> – Update on weekly insulin Efsitora</p> <p><u>Chantal Mathieu</u> – CGM derived data on weekly insulins</p>	<p><u>Laurel Messer</u> - Technology pearls for professionals</p> <p><u>Steven Edelman</u> – Top 10 tips to help people with diabetes (PwD) stay in range</p> <p><u>Steven Edelman and Jeremy Pettus</u> – Rapid fire interpretations of CGM downloads</p>			
10:30-11:00	COFFEE BREAK, EXHIBITION & E-POSTERS								

11:00-12:30	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
12:30-13:30	LUNCH BREAK, EXHIBITION & E-POSTERS
13:30-15:00	PLENARY 2 ATTD YEARBOOK SESSION
	<p><u>Klemen Dovc</u> - Continuous and intermittent glucose monitoring</p> <p><u>Rayhan A. Lal</u> - Insulin delivery hardware: pumps and pens</p> <p><u>Lutz Heinemann</u> - New insulins, biosimilars and insulin therapy</p> <p><u>Mark Clements</u> - Closed-loop, artificial intelligence-based decision support systems and data science</p> <p><u>Mark Clements</u> - Using digital health technology to prevent and treat diabetes</p> <p><u>Jennifer M. Yamamoto</u> - Technology and pregnancy</p> <p><u>David M. Maahs</u> - Diabetes technology and therapy in the pediatric age group</p> <p><u>Dessi P. Zaharieva</u> - Advances in exercise and nutrition as therapy in diabetes</p> <p><u>Thomas W. Martens</u> - Primary care and diabetes technologies and treatments</p> <p><u>Medha Munshi</u> - Use of technologies at the advanced age</p> <p><u>Ananta Addala</u> - Diabetes technology in the "real world": Expanding access and addressing disparities</p> <p><u>Alon Liberman</u> - Diabetes technology and the human factor</p> <p><u>Desmond Schatz</u> - Immune interventions and restorative therapies in type 1 diabetes</p> <p><u>Viral N. Shah</u> - Obesity, NAFLD/NASH and diabetes</p> <p><u>Satish K. Garg</u> - Virtual clinics for diabetes care</p> <p><u>Satish K. Garg</u> - New medications for the treatment of diabetes</p>
15:00-15:15	Break
15:15-16:45	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)
16:45-17:15	COFFEE BREAK, EXHIBITION & E-POSTERS

17:15-18:45	PARALLEL SESSION 17 OBESITY IN TYPE 1 DIABETES	PARALLEL SESSION 18 AUTOMATED INSULIN DELIVERY IN CHILDREN	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	PARALLEL SESSION 19 SELF MANAGEMENT OF DIABETES <small>(17:15-18:05)</small>	PARALLEL SESSION 20 CGM GUIDED PRECISION DIABETES MANAGEMENT	PARALLEL SESSION 21 INTEROPERABILITY OF DIABETES TECHNOLOGY	PARALLEL INDUSTRY SYMPOSIUM <small>(not included in the main event CME/CPD credit)</small>	ORALS 5
	<p>Satish Garg - Management options for treating obesity in type 1 diabetes patients</p> <p>Jeremy Pettus - Insulin resistance in type 1 diabetes: An underappreciated problem</p> <p>Kirsten Nørgaard - Effects of GLP1 in type 1 diabetes</p> <p>Victor Gerdes - Bariatric surgery in diabetes</p>	<p>Revital Nimri - Maximizing glycemic control with automated insulin delivery in young children</p> <p>Thomas Danne – Worldwide progress achieving treatment targets in children with type 1 diabetes</p> <p>Ivana Rabbone - Technology in the changing management of diabetes in children</p> <p>Nataša Bratina - Data on diabetes treatment in children below the age of six</p>		<p>Mark Clements – Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior</p> <p>John Leth - The potential of open-source software in diabetes research</p> <p>Heiko Peuscher - A survey on existing open-source projects in diabetes simulation</p> <p>Short Break</p> <p>PARALLEL SESSION 20 TECH IT OUT OF THE BOX: PAPERS, POLICY, PATIENTS <small>(18:15-18:45)</small></p> <p>Introduction</p> <p>Partha Kar - Challenges of getting technology into policy</p> <p>Eleanor Scott - CGM in Pregnancy</p> <p>Jazz Sethi - D-Coding tech research into reality</p>	<p>Tara Ettestad - CGM Guided Nutrition</p> <p>Michael Riddell - CGM guided exercise</p> <p>Thomas Martens – CGM guided insulin management</p> <p>Darja Šmigoc Schweiger - Guided management of diabetes in female</p>	<p>David Klonoff – Interoperability of diabetes technology Academic view</p> <p>Alexander Olbrechts - Interoperability of diabetes technology - A company's view</p> <p>Johan Jendle - Interoperability of diabetes technology - Regulatory hurdle</p> <p>Tim Street – Interoperability of diabetes technology - Patient's view</p>		
18:45-18:55								
18:55-20:25	IGNITE Start-up Networking Event (not included in the main event CME/CPD credit)				ATTD Partner Event (not included in the main event CME/CPD credit)			

Saturday, 9 March, 2024

08:30-09:20	PLENARY INDUSTRY SYMPOSIUM (not included in the main event CME/CPD credit)						
09:20-09:30	Break to Change Halls						
09:30-11:00	PARALLEL SESSION 23 DECISION SUPPORT AND AUTOMATED INSULIN DELIVERY FOR THE MANAGEMENT OF TYPE 2 DIABETES	PARALLEL SESSION 24 CHALLENGES IN METABOLIC CONTROL	ORALS 6	PARALLEL SESSION 25 CGM CLINICAL WORKFLOW	PARALLEL SESSION 26 SCREENING, INTERVENTION AND PREVENTION OF TYPE 1 DIABETES (2)	PARALLEL SESSION 27 NUTRITION AND FOOD TECHNOLOGIES	ORALS 7
	<p><u>Chiara Fabris</u> - Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D</p> <p><u>Lia Bally</u> - Virtual clinic for insulin therapy in type 2 diabetes</p> <p><u>Morten Hasselstrøm Jensen</u> - Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project</p>	<p><u>Richard Bergenstal</u> - We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia</p> <p><u>Elisabeth Selvin</u> - Diabetes and cognitive decline and dementia</p> <p><u>Francesco Giorgino</u> - Addressing glucose patterns in type 2 diabetes: Opportunities and challenges</p> <p><u>Nebojsa Lalic</u> - Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease</p>		<p><u>David Maahs</u> - Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study</p> <p><u>Amy Criego</u> – CGM Success: Device start and ongoing data management to improve patient care</p> <p><u>Nana Jones</u> - Integration of CGM data into the EMR – Challenges and successes</p> <p><u>Xavier Cos</u> - Use of CGM by the primary care providers</p>	<p><u>Emanuele Bosi</u> – Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool?</p> <p><u>Laura Jacobsen</u> – Immune therapy – Predicting responders/non-responders</p> <p><u>Jennifer Sherr</u> – Teplizumab therapy in the real world</p> <p><u>Raffaella Buzzetti</u> – Antibody positivity in adult population</p>	<p><u>Michal Gillon-Keren</u> - Facilitate carb counting for people with diabetes</p> <p><u>Laya Ekhlaspour</u> - Beyond carbohydrate counting: Optimizing mealtime insulin dosing</p> <p><u>Peter Jacobs</u> - Unannounced meal detection algorithms: Can we eliminate manual meal boluses?</p> <p><u>Daria Igudesman</u> - Diet, microbiome, obesity and type 1 diabetes</p>	

11:00-11:30	COFFEE BREAK, EXHIBITION & E-POSTERS							
11:30-13:00	PARALLEL SESSION 28 TO CGM OR NOT TO CGM?	PARALLEL SESSION 29 SPORT IN DIABETES	ORALS 8	PARALLEL SESSION 30 GENDER DIFFERENCES IN DIABETES MANAGEMENT AND GLUCOSE CONTROL	PARALLEL SESSION 31 JDRF CELL REPLACEMENT THERAPY	PARALLEL 32 ADVANCES IN TREATING DIABETES	PARALLEL SESSION 33 TECHFAIR WINNERS' PRESENTATIONS	ORALS 9
	<p>Tadej Battelino - CGM derived criteria for stage 2 type 1 diabetes</p> <p>Leon Farhy – Diagnostic CGM</p> <p>Anders Carlsson - The use of CGM in prediabetes and obesity</p> <p>Dario Rahelic - Use of CGM in nutrition management in type 2 diabetes</p>	<p>Klemen Dovc - Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability</p> <p>Michael Riddell - Lessons learned from the ongoing type 1 diabetes exercise research initiative</p> <p>Kirsten Nørgaard - Low-dose glucagon to prevent hypoglycemia during exercise</p> <p>Dessi Zaharieva - Translation of exercise guidelines into practical applications for type 1 diabetes</p>		<p>Eda Cengiz - Update on diabetes Female Technology (femtech)</p> <p>Chiara Fabris - What do women want (and need)? Results from the large-scale IMAGINE survey</p> <p>Jane Yardley - Challenges of exercise in women with type 1 diabetes</p> <p>Brynn Marks - Insulin delivery is automated, but the education is not: Mothering diabetes technology users</p>	<p>Ester Latres - Introduction</p> <p>Peter Senior - 20-Year Outcomes of Islet Cell Transplantation - the benchmark for stem cells?</p> <p>Qizhi Tang - Engineering beta cells to enable immunosuppression-free replacement therapy for type 1 diabetes</p> <p>José Oberholzer - Islet cell replacement therapy for type 1 diabetes</p> <p>Round Table</p>	<p>Peter Adolfsson - Current use of connected pens</p> <p>Fernando Gómez Peralta - Connected insulin pens and caps: An expert's recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN)</p> <p>Christophe de Block – Ketone continuous measurement – Is it needed?</p> <p>Andrea Facchinetti - Digital twin technologies for treating diabetes</p> <p>Neal Kaufman - The importance and impact of family caregivers on a variety of outcomes for people with diabetes</p>		

13:00-13:45	LUNCH BREAK, EXHIBITION & E-POSTERS						
13:45-15:15	PARALLEL SESSION 34 OBESITY AND TYPE 2 DIABETES	PARALLEL SESSION 35 DIABETES IN ITALY	ORALS 10	PARALLEL SESSION 36 ISPAD/ATTD SESSION DIABETES TECHNOLOGY IN LOWER INCOME COUNTRIES	PARALLEL SESSION 37 DTECH SYMPOSIUM - DIABETES IN INDIA	PARALLEL SESSION 38 SARCOPENIA, FRAILTY AND DIABETES	ORALS 11
	<p><u>Antonio Ceriello</u> - Weight and glycemc variability: Bad companions for CVD development in diabetes</p> <p><u>Barbara McGowan</u> - Medical therapies for treatment of obesity</p> <p><u>Jernej Kovac</u> - Genetic background of obesity</p> <p><u>Kamlesh Khunti</u> - Early intervention for type 2 diabetes in primary care</p>	<p><u>Marco Marigliano</u> - Relationships between insulin delivery system, CGM satisfaction and glucometrics</p> <p><u>Andrea Scaramuzza</u> - Real-world data in very young AHCL users - Comparison among different systems</p> <p><u>Nicola Minuto</u> - Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough</p> <p><u>Sergio di Molfetta</u> - CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated</p>		<p><u>Renza Scibilia</u> – Type 1 diabetes global index and overview of diabetes technology present and future in lower income countries</p> <p><u>Thereza Piloya-Were</u> - Impact of CGM in East Africa, research and translation</p> <p><u>Hamidah Nabakka</u> - Diabetes advocate perspective on diabetes technology in low-income countries</p>	<p><u>Banshi Saboo</u> - Welcome and introduction to Dtech symposium</p> <p><u>Shashank Joshi</u> - Artificial intelligence in diabetes care</p> <p><u>Jothydev Kesavadev</u> - 25 years of telemedicine vs. conventional care in diabetes: Assessing vascular complications and quality of life</p> <p><u>Manoj Chawla</u> - Optimizing real time CGM in self-pay markets</p> <p><u>Amit Gupta</u> - Challenges and opportunities in digital diabetes care in India</p> <p><u>Mithun Bhartia</u> - Diabetes and sex life – The role of technology to improve quality of life</p> <p><u>Rakesh Parikh</u>: Artificial Intelligence in the management of diabetes</p>	<p><u>Alan Sinclair</u> - Diabetes, sarcopenia and frailty: Interrelationships and clinical importance</p> <p><u>Leocadio Rodríguez Mañas</u> - Current treatment options for sarcopenia in the context of frail older people with diabetes</p> <p><u>Tali Cukierman-Yaffe</u> - How to measure and monitor sarcopenia and frailty</p> <p><u>TBC</u> - Current and investigational medication for sarcopenia</p>	

15:15-15:25	Break to Change Halls
15:25-16:25	PLENARY 3 CURE OF DIABETES
	<u>Michael Haller</u> - Cost effectiveness of immune therapies in preserving beta cell function – Real world applications <u>Jay Skyler</u> - Stem cell approaches to type 1 diabetes <u>Michael Rickels</u> - Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes
16:25-17:00	CLOSING REMARKS
17:00	FAREWELL REFRESHMENTS